Updates

Community post

Adaptive Phage Therapeutics (APT) announced that the FDA has accepted its Investigational New Drug (IND) application for PhageBank™ phage therapy for the treatment of Diabetic Foot Osteomyelitis (DFO). This is the third successful IND application by APT in the last year!

SourceCapsid & Tail #117